As Osiris moves on from fraudulent past, one exec settles up with SEC

Two years after the SEC charged four Osiris Therapeutics execs for cooking the books to fabricate a rosy picture at the company, federal regulators have handed down their first judgment.

Bobby Dwayne Montgomery, the former chief business officer at Osiris, has agreed to pay a civil penalty of $40,000 and be legally barred from future violations of securities laws, including those that prohibit falsifying books and records and lying to auditors.